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INTRODUCTION
Platelet-activating factor (PAF, is one of the most active lipid species identified to date. It was first discovered in the early 1970's as a bioactive lipid generated by basophils capable of inducing platelet aggregation and anaphylaxis (Benveniste et al., 1972) . Specifically, levels of PAF have been shown to directly correlate to the severity of anaphylaxis (Vadas et al., 2008) . In addition, PAF plays important roles in inflammation. PAF is produced by a variety of cells, including neutrophils. These effects are thought to be mediated by a G protein-coupled PAF receptor (Honda et al., 1991; Hwang et al., 1983) .
Because of the potent and sometimes deleterious biological effects, PAF synthesis is tightly regulated. PAF is not stored in large amounts in the cell, and its production is induced by proinflammatory factors (Szabo et al., 1993) . The induced synthesis of PAF involves the de novo pathway and remodeling pathway, the latter being responsible for the majority of PAF induced by inflammatory stimuli (Reinhold et al., 1989) . In this process, PLA 2 cleaves membrane phospholipids at the sn-2 position and yields several lipid products, including lysoPAF (1-O-hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine). The highly specific PAFacetyltransferase (PAF-AT) then adds an acetyl group to the sn-2 position to yield PAF (Shindou et al., 2007) . PAF is subsequently degraded through removal of the acetyl group by PAFacetylhydrolases (PAF-AH) (Karasawa et al., 2003) . The PAF-AH mediated conversion to lysoPAF is a primary pathway for PAF inactivation, and there have been efforts in the exploration of PAF-AH as a potential therapeutic agent (Arakawa et al., 2005; Gomes et al., 2006; Quarck et al., 2001) . The levels of PAF-AH are inversely correlated with the severity of This article has not been copyedited and formatted. The final version may differ from this version. (Vadas et al., 2008) , and the administration of human recombinant PAF-AH can inhibit several mouse models of anaphylaxis (Fukuda et al., 2000) .
Although lysoPAF is thought to lack bioactivity and is often used as a control in experiments exploring PAF function, it has not been carefully studied in its own context. Given that lysoPAF levels are inversely related to those of PAF, and that it is a metabolite as well a precursor of PAF, there seems to be a need to understand any potential activity that this lipid may have. Furthermore, the potential therapeutic use of recombinant PAF-AH in humans requires a comprehensive understanding of the cellular functions of the lipid produced by this enzyme. In the course of a study of neutrophil activation by bioactive lipids, we found that lysoPAF exhibits an inhibitory effect on neutrophil superoxide production. Further investigation has led to the discovery of lysoPAF-induced intracellular cAMP production as a potential mechanism for its inhibitory effect. Moreover, treatment of platelets with lysoPAF reduces their aggregation following low dose thrombin stimulation. These data suggest that lysoPAF balances some of the bioactivities of PAF, and the beneficial effects of PAF-AH may be attributed in part to this negative regulatory function of lysoPAF. 
MATERIALS AND METHODS
Materials
Preparation of neutrophils.
Human peripheral blood was collected from healthy donors by venipuncture, using a protocol approved by the Institutional Review Board at University of Illinois at Chicago. Acid citrate dextran was used as anti-coagulant. Neutrophil isolation was carried out using discontinuous Percoll gradient (Lin et al., 2005) . For preparation of mouse neutrophils, mice were anesthetized with CO 2 and sacrificed by cervical dislocation. Femurs and tibias of wild type and PAFR -/-littermate mice, on a C57Bl6 background, were isolated and placed in HBSS-Prep (HBSS, 0.5% FBS, 10mM HEPES, and 1% Glucose). Bone marrow was then harvested, marrow was disaggregated, and then cells were separated by centrifugation using a discontinuous density gradient consisting of 3 ml NycoPrep 1.077 (Axis-Shield) underlayed with 72% Percoll (Amersham Biosciences). Neutrophils were collected at the NycoPrep-Percoll interface, and washed 2x with HBSS-Prep. Final resuspension was in 0.5% BSA in RPMI medium. Purity of neutrophils was consistently at 80% or above, as determined by FACS scatter, Wright staining, and Hemavet (Drew Scientific).
Preparation of human platelets. Blood was taken as described above with approval.
Acid citrate dextran was used as an anti-coagulant. Platelet isolation was performed as described previously (Li et al., 2006) .
Superoxide generation.
Human PMN superoxide generation was measured by isoluminol-enhanced chemiluminescence as described previously (Lin et al., 2005) .
Chemiluminescence was measured every minute using a Wallac Multilabel Counter plate reader (Perkin Elmer Life Sciences, Boston, MA). Unstimulated controls were recorded This article has not been copyedited and formatted. The final version may differ from this version. well) were pre-incubated with vehicle, lysoPAF (1μM) or PAF (1μM) for ten min prior to addition to endothelial cell monolayers. The electrode was then connected and the resistance was monitored as described previously (Tiruppathi et al., 1992) . Then, fMLF (1 μM) was added to indicated samples and the recording continued for a further 5 hours.
Calcium mobilization. Increase in intracellular calcium was detected using Indo-1/AMlabeling of human PMNs kept in a 0.5% BSA/HBSS buffer as described previously (He et al., 2003) .
cAMP assay. cAMP was measured using a competitive enzyme-linked immunosorbent assay (Biomol) as described previously (Lin et al., 2005) .
Platelet aggregation. Platelet aggregation was measured as described previously (Li et al., 2006) . Briefly, washed human platelets, at a concentration of 3x10 8 /mL, were pre-treated with lysoPAF (10 nM to 1 μM) or control for 2 minutes, then stimulated with α-thrombin from Enzyme research laboratories (South Bend, IN).
Statistical analysis. Data were analyzed by unpaired student t test using Prism (ver.4.0) software from GraphPad, San Diego, CA.
This article has not been copyedited and formatted. The final version may differ from this version. (Dewald and Baggiolini, 1985; Vercellotti et al., 1988) . This "priming" effect is evident in human neutrophils first incubated with PAF and then stimulated with fMLF, a full agonist of neutrophils ( Figure 1A ). In PAF-treated neutrophils, fMLF (1 μM)-induced superoxide production was 2.85-fold higher than the level in buffer-treated cells (p < 0.01), based on isoluminol-enhanced chemiluminescence (ECL) ( Figure 1A , 1B). LysoPAF, widely considered a non-active PAF metabolite and precursor, is often used as a negative control in studies of the bioactivity of PAF. When superoxide production in lysoPAF-treated neutrophils was set as baseline (open bar in Figure 1B ), the "priming" effect of PAF became more evident (a 6.92-fold increase) following fMLF stimulation (p < 0.01). LysoPAF (1 μM) caused a 57% reduction of the fMLF-induced superoxide production when compared to buffer-treated neutrophils under the same experimental conditions ( Figure 1A , 1B). These results suggest that lysoPAF is bioactive and produces an inhibitory effect on fMLF-induced neutrophil superoxide production.
The alkyl group in PAF and lysoPAF is connected through an ether linkage at the C1 position to a carbon chain of variable lengths. In the above study, 16:0 PAF and lysoPAF was used. To determine whether the length of the carbon chain affects the bioactivity of lysoPAF, we examined 18:0 lysoPAF from the same source and found it to be equally effective in the inhibition of fMLF-induced superoxide production ( Figure 1C ). Next, we determined the potency of PAF and lysoPAF in superoxide production assays. Both PAF and lysoPAF This article has not been copyedited and formatted. The final version may differ from this version. 8 exhibited bioactivity at concentrations as low as 10 nM. The opposing effects of PAF and lysoPAF on superoxide production continue to increase up to the concentration of 1 μM ( Figure   1D ).
Neutrophil activation can lead to microendothelial injury, manifested as increased endothelial permeability and loss of barrier function. These changes are seen during Gramnegative bacterial infection and in numerous inflammatory disorders such as adult respiratory distress syndrome (Lee and Downey, 2001 ). In addition, pulmonary edema is one of the hallmarks of anaphylaxis. We determined the effects of PAF and lysoPAF on neutrophildependent changes of endothelial permeability by measuring transendothelial electrical resistance (TER), a well established in vitro assay of endothelial barrier function (Furie et al., 1984; Tiruppathi et al., 1992) . In this assay, changes in TER reflect the integrity of the endothelial monolayer, which is compromised in the presence of reactive oxygen species from activated neutrophils. As shown in Figure 2A , fMLF stimulation of neutrophils caused a decrease in TER over time, and this change was further enhanced by pretreatment of neutrophils with PAF (1 μM). In contrast, lysoPAF used at the same concentration significantly reduced the fMLF-stimulated decrease in TER while having no significant effect on TER when applied alone with vehicle control before stimulation with fMLF ( Figure 3A) . The results indicated that lysoPAF did not induce Ca 2+ mobilization in neutrophils, and treatment of neutrophils with lysoPAF had no effect on the fMLF-induced Ca 2+ mobilization. These results preclude that lysoPAF blocks the fMLF interaction to FPR.
To rule out the possibility that the inhibitory effect of lysoPAF is specifically targeted at FPR signaling pathways, we investigated whether lysoPAF affects C5a signaling. Stimulation of neutrophils with C5a caused superoxide production ( Figure 3B , filled squares). In cells treated with PAF, the C5a-induced superoxide production was markedly increased (filled circles). In contrast, lysoPAF treatment markedly decreased the C5a-induced superoxide production (filled triangles). Therefore, the inhibitory effect of lysoPAF is not confined to one chemoattractant receptor.
The inhibitory effect of lysoPAF is independent of the PAF receptor. Because of the structural similarity between PAF and lysoPAF, we investigated whether the inhibitory effects of lysoPAF are mediated through the PAF receptor. When neutrophils were exposed to both PAF and lysoPAF at equal molar concentrations, the effect of the individual lipids was negated ( Figure 4A ). To determine whether lysoPAF directly affects PAF receptor (PAFR)-mediated signaling, we conducted a Ca 2+ mobilization assay, in which neutrophils were treated with lysoPAF before measurement of PAF-induced increase in intracellular Ca 2+ concentration. As shown in Figure 4B , lysoPAF did not induce Ca 2+ mobilization, and it produced no effect on PAF-induced Ca 2+ mobilization. We also used a PAF receptor antagonist, SR27417 (Herbert et al., 1991) , to determine whether blocking PAFR could alter the effects of PAF and lysoPAF on fMLF-induced superoxide production. Neutrophils were incubated in the presence or absence of SR27417 (10 nM) and either PAF or lysoPAF, and then stimulated with fMLF. As shown in This article has not been copyedited and formatted. The final version may differ from this version. Figure 3C , SR27417 abrogated PAF priming in the neutrophils, but did not change the inhibitory effect of lysoPAF. This result argues against the notion that lysoPAF competes with PAF in utilizing PAFR, although it does not rule out the possibility that lysoPAF may interact with the receptor at a site different from the PAF binding site. This latter possibility was tested using neutrophils derived from PAFR knockout mice (Ishii et al., 1998) . As shown in Figure 4D , genetic deletion of the PAFR gene abolished the priming effect of PAF, but did not alter the inhibitory effect of lysoPAF, on fMLF-induced superoxide production. Taken together, results from these experiments indicate that inhibition by lysoPAF is independent of PAFR.
LysoPAF activates adenylyl cyclase and increases intracellular cAMP concentration in neutrophils. Molecular characterization of PAFR has led to the identification of its signaling pathways that include functional coupling to the Gq class of G proteins, activation of PLCβ, and induction of second messengers inositol (1,4,5)-trisphosphate and diacyl glycerol (Honda et al., 2002) . PAFR also couples to the Gi class of G proteins that mediate the chemotactic and crossregulatory signals and also contribute to the activation of PLCβ and exocytosis in transfected RBL-2H3 cells with the G proteins fused to the PAFR (Brown et al., 2006) . As a result, PAF stimulation leads to Ca 2+ mobilization in neutrophils. We have shown that stimulation of neutrophils with lysoPAF does not cause increase in intracellular Ca 2+ concentration ( Figure 4B ), suggesting differences between PAF and lysoPAF in the activation mechanism and the utilization of downstream effectors. Because several anti-inflammatory molecules stimulate the adenylyl cyclase -cAMP-signaling pathway (Fantone et al., 1983; Fantone et al., 1984; Rivkin and Becker, 1976) , we tested whether lysoPAF could activate this pathway and increase cAMP concentration in human neutrophils. As shown in Figure 5A , stimulation of neutrophils with lysoPAF resulted in dose-dependent increases in intracellular cAMP concentrations that reached This article has not been copyedited and formatted. The final version may differ from this version. up to 2-fold above baseline. It is possible that lysoPAF activates a Gαs-coupled receptor, leading to cAMP production. This is suggested by the observation that cholera toxin, which ADP ribosylates and activates Gαs, increased cAMP level to the same extent as in lysoPAFstimulated cells ( Figure 5B ). Likewise, cholera toxin dose-dependently inhibited fMLFstimulated superoxide production ( Figure 5C ). Pertussis toxin, which ADP ribosylates the Gαi proteins and interferes with GαI -receptor interaction, had no effect on lysoPAF-induced elevation of cAMP concentration.
The involvement of an adenylyl cyclase is suggested by the results from experiments using the adenylyl cyclase inhibitor SQ22536 (9-(tetrahydro-2-furyl)adenine) (Graber and Hawiger, 1982) , which dose-dependently reversed the inhibitory effect of lysoPAF on the production of syperoxide ( Figure 5D ). Protein kinase A (PKA), a key kinase activated by cAMP, also plays a role in the inhibition by lysoPAF. Using the PKA inhibitor H-89, we observed a partial restoration (p < 0.05) of superoxide production in fMLF-stimulated neutrophils that were pretreated with lysoPAF ( Figure 5E ). This result is confirmed in a parallel experiment using another PKA inhibitor, KT5720, which produced similar effect in reversal of the effect of lysoPAF. These results indicate that lysoPAF signaling involves adenylyl cyclasemediated generation of cAMP, and that PKA contributes to the inhibitory effect of lysoPAF.
LysoPAF induces cAMP elevation in platelets and inhibits platelet aggregation. In addition to neutrophils, other blood cells including platelets are involved in inflammatory responses. PAF was originally named for its activating effect on platelets (Benveniste et al., 1972) . However, a bioactivity of lysoPAF on platelets has not been reported. We conducted experiments to determine whether lysoPAF could affect the intracellular cAMP levels in platelets, and if treatment of platelets with lysoPAF would affect its activation. In washed This article has not been copyedited and formatted. The final version may differ from this version. 12 human platelets, lysoPAF induced a significant increase in cAMP levels (p < 0.01) ( Figure 6A ), whereas PAF does not have an effect on the intracellular cAMP levels in platelets under the same experimental conditions. Similar to neutrophils, cAMP inhibits many activation processes in platelets, including platelet aggregation (Salzman et al., 1972) . We therefore tested whether lysoPAF-treated platelets display changes in agonist-induced platelet aggregation. When washed platelets were pre-incubated with lysoPAF and then stimulated with α-thrombin (0.03U/ml), a lysoPAF dose-dependent inhibition in platelet aggregation was observed ( Figure 6B ). Also similar to neutrophils, PKA is known to be involved in downstream signaling of cAMP. The inhibitory effect of lysoPAF on thrombin-induced platelet aggregation is partially reversed by the PKA inhibitors H-89 and KT5720 ( Figure 6C ).
DISCUSSION
Results from this study demonstrate that lysoPAF is bioactive and produces an effect opposite of that of PAF in neutrophil superoxide production. Whereas PAF potentiates NADPH oxidase activation and superoxide production, lysoPAF inhibits this function. The inhibitory effect of lysoPAF does not depend on PAFR, and is not limited to a particular agonist such as fMLF or one cell type such as neutrophils. In our experiments, the C5a-stimulated neutrophil superoxide production and thrombin-induced platelet aggregation are also inhibited by lysoPAF.
These observations are novel, and provide evidence for a possible function of lysoPAF in balancing the proinflammatory activities of PAF. While PAF plays important roles in regulating cellular functions, its proinflammatory activities require temporal regulatory mechanisms including induced synthesis and efficient degradation. Therefore, enzymes responsible for PAF synthesis and degeneration, mainly the PAF-ATs and PAF-AHs, are potential targets of This article has not been copyedited and formatted. The final version may differ from this version. (Henderson et al., 2000) .
Previous studies of the bioactivity of PAF often included lysoPAF as a negative control.
Other reports showed that lysoPAF displayed PAF-like activities in stimulating DNA synthesis in smooth muscle cells (Chai et al., 2000) and microvascular leakage when administered to guinea pigs by inhalation (Sakamoto et al., 1993) . These PAF-like activities, including the ability to induce Ca 2+ mobilization, were blocked by PAFR antagonists, indicating that they are mediated by the identified PAFR (Sakamoto et al., 1993 ). Marathe and colleagues have shown that treatment of the bioactive lysoPAF and lysoPC with PAF-AH or with saponification abolishes the activities of these lysophospholipids, indicating that these activities come from contaminating phospholipids (Marathe et al., 2001) . Before chemically synthesized PAF became widely available, many studies were conducted using PAF isolated from crude methanol extracts of cells or egg yolk, and those studies were prone to contamination with PAF-like phospholipids.
The same methods apparently contributed to the identification of lipids migrating with a similar R f as PAF on thin-layer chromatography and containing both platelet-activating and neutrophilinhibiting properties (O'Donnell et al., 1981) . To eliminate contaminations with other phospholipids, in this study we used synthetic lysoPAF and PAF from the same source, and prepared stock solutions for both lipids using exactly the same method. Experiments that compared lysoPAF and PAF were strictly carried out in parallel. Our study has shown dosedependent inhibition of neutrophil NADPH oxidase activation by lysoPAF, with minimal active This article has not been copyedited and formatted. The final version may differ from this version. The exact mechanism by which lysoPAF exerts its bioactivity is still unknown. As the first step towards an answer to this question, we determined whether elevation of intracellular cAMP level contributes to the inhibitory effects of lysoPAF. Our results confirmed that lysoPAF, but not PAF, was able to stimulate an increase in cAMP levels in both neutrophils and platelets. Moreover, pharmacological inhibition of PKA, an effector of cAMP, partially reversed the inhibitory effect of lysoPAF, indicating that the cAMP-PKA pathway is involved, but PKAindependent mechanism may also exist. We also found that treating neutrophils with SQ22536, an inhibitor of adenylyl cyclase, dose-dependently reversed the inhibitory effect of lysoPAF on superoxide generation. These results confirm that adenylyl cyclase-mediated production of cAMP is key to the inhibitory activity of lysoPAF. These effects are not likely the results of non-specific actions of the inhibitors on other kinases, most of which are important for neutrophil NADPH oxidase activation and platelet aggregation.
We hypothesize that lysoPAF activates adenylyl cyclase through either one or both of the following pathways. First, lysoPAF may bind to a receptor that couples to the Gs class of G proteins. Because Gαs activates adenylyl cyclase, lysoPAF binding to this receptor leads to increased cAMP production. This is likely given the emergence of an increasing number of GPCRs for bioactive lipids (Im, 2004) . Our study using cholera toxin, which activates Gαs, produced similar effect in the elevation of cAMP levels and inhibition of superoxide generation as seen in lysoPAF-stimulated cells. To determine which receptor(s) is activated by lysoPAF, we have conducted an exhaustive search of the existing GPCR database and identified 28
receptors that are related in sequence to known lipid receptors. These receptors were This article has not been copyedited and formatted. The final version may differ from this version. G2A has been shown to mediate the bioactivity of lysoPC (Lin et al., 2005; Wang et al., 2005) , although it lacks certain pharmacological properties of a receptor such as direct binding of lysoPC (Kabarowski et al., 2001; Witte et al., 2005) . When tested in our assays, G2A and structurally similar receptors such as GPR4, TDAG8 and OGR1, did not respond significantly to lysoPAF stimulation (Supplemental Table I ). Other GPCRs tested also failed to respond to lysoPAF in these functional assays. Therefore, screening of additional GPCRs will be necessary to further test the hypothesis. We noticed that fMLF, which activates a Gi-coupled receptor FPR, is reported to enhance intracellular cAMP levels through a pertussis toxin-sensitive mechanism (Ali et al., 1998) . However, fMLF also stimulates Ca 2+ flux whereas lysoPAF does not, indicating that lysoPAF does not activate the same signaling pathway that is induced by fMLF. Nevertheless, expanding the search to other GPCRs may be beneficial to understanding of how lysoPAF induces cAMP elevation. The second possible mechanism for the inhibitory effect of lysoPAF involves direct activation of adenylyl cyclase. To date, ten isoforms of transmembrane adenylyl cyclase have been identified (Hurley, 1999) . Adenylyl cyclase isoform 1 expression is restricted to the brain. Isoforms 6 and 7 are ubiquitously expressed in cells and tissues. We have tested several other cell types, including HPMECs, which were unable to respond to lysoPAF with increased cAMP levels (data not shown). Therefore, it is unlikely that the candidate is a ubiquitously expressed isoform of adenylyl cyclase. Store operated calcium channels are known to activate adenylyl cyclase isoforms 3 and 8; however we observed no changes in calcium levels in cells treated with lysoPAF. A further analysis is required to more carefully examine these cyclase isoforms.
This article has not been copyedited and formatted. The final version may differ from this version. Recent cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase (Shindou et al., 2007) and clinical correlation between lowered PAF-AH concentration and severity of anaphylaxis (Vadas et al., 2008) are expected to promote continued exploration of PAF-AH and related pathways. The discovery of lysoPAF as having opposite activities of PAF in the functional assays performed in this study may contribute to a better understanding of these phospholipids for their functions in human physiology. This article has not been copyedited and formatted. The final version may differ from this version. 
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